Pipobroman

DB00236ApprovedSmall molecule

An antineoplastic agent that acts by alkylation.

Mechanism: The mechanism of action is uncertain, but due to the structural similarity with other DNA alkylating agents, pipobroman is thought to alkylate DNA leading to disruption of DNA synthesis and eventual cell death.
Curator reviewed · 1 reference
Primary indication: For the treatment of polycythaemia vera and refractory chronic myeloid leukaemia.Curator reviewed · 1 structured indication
Formula / weight: C₁₀H₁₆Br₂N₂O₂ · 356.054 g/mol (avg)
Code names: A-8103 · NSC-25154

Resolves to

Compound

UNII6Q99RDT97RCAS54-91-1ChEMBLCHEMBL1585ChEBI8242PubChem4842KEGGD00467

Clinical / RWD

RxNorm8347ATCL01AX02PharmGKBPA164747673

Structure

InChIKeyNJBFOOCLYDNZJN-UHFFFAOYSA-NSMILESBrCCC(=O)N1CCN(CC1)C(=O)CCBr

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

38Drug interactionsStructured to mechanism, not free text

1Structured indicationCondition, population, route and combination as fields, not prose

2Marketed productsAcross 1 country and 2 labellers

1ATC codeIncluding every combination product, plus 7 drug categories

4+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Pipobroman, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In